The Centers for Disease Control and Prevention (CDC) has paused all new vaccine recommendations following a dramatic shake‑up by Health Secretary Robert F. Kennedy Jr. The move marks the first time in six decades that the agency’s Advisory Committee on Immunization Practices (ACIP) has been dismantled.
Federal leadership reshapes vaccine oversight
President Trump appointed Kennedy to oversee the CDC and other health agencies. Last year Kennedy dismissed the long‑standing ACIP and replaced it with a panel that included several anti‑vaccine voices. A federal judge subsequently ruled that Kennedy likely violated federal procedures, ordering the panel shut down and suspending his plan to cut the number of childhood vaccines.
With the ACIP no longer meeting publicly to review data, the CDC has been left without a clear mechanism to formalize new vaccine policies. “Even when credible evidence reaches a tipping point, we lack an obvious process to formalize that change,” said Yale health‑policy researcher Jason Schwartz.
Impact on new flu vaccine and other shots
The FDA recently granted full approval for mFlusiva, the first mRNA‑based flu vaccine for adults aged 50‑64. Despite the approval, the CDC has not added mFlusiva to its list of recommended flu shots for the upcoming season, citing “legal uncertainties and inquiries.” Private medical societies, however, are recommending the product as an option.
Other vaccine discussions have also stalled. The CDC’s role in the Vaccines for Children (VFC) program— which pays for shots for uninsured kids—remains unchanged, and the agency has not clarified whether updated COVID‑19 boosters will be covered under VFC.
HPV vaccine reassessment delayed
In 2024 the ACIP began a review of the human papillomavirus (HPV) vaccine schedule, exploring whether a single dose might suffice for girls. Kennedy’s abrupt termination of the committee halted that work, and a court order later suspended his unilateral decision to reduce the recommended doses to one.
Experts from the American Academy of Pediatrics continue to evaluate the data, but the broader policy debate remains in limbo.
Medical community reaction
Many physicians and health organizations welcomed the court’s intervention, viewing it as a return to a transparent, evidence‑driven process. Dr. Jason Goldman, president of the American College of Physicians, said the decision should “mean a return to a transparent and evidence‑driven process that safeguards the health of all communities and the best interests of our patients.”
Nevertheless, some observers note that the credibility of the Trump administration’s vaccine guidance has been damaged among mainstream medical professionals, making any future recommendations subject to heightened scrutiny.
Potential policy changes on the horizon
According to a Department of Health and Human Services spokesperson, the administration is still considering revisions to how the federal government categorizes vaccine recommendations, though no specific proposal has been released. Public comments on the matter were due earlier this week.
An alliance of fifteen Democratic governors warned that rapid, federally driven changes could increase confusion and administrative burdens for state health departments, potentially leading to higher disease‑outbreak risk.
As the debate continues, doctors, insurers, and families await clearer guidance on which vaccines will be covered and recommended for the upcoming flu season and beyond.
Original reporting: KTBS 3 (Shreveport) — read the source article.
